# Nuclide record select-lenvatinib (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/select-lenvatinib/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "select-lenvatinib", "NCT01321554" ;
  schema:name "SELECT"@en ;
  schema:description "Turned lenvatinib into the main drug for thyroid cancers that no longer take up radioactive iodine, quadrupling the time before the disease grew."@en ;
  schema:url <https://nuclide.cc/trials/select-lenvatinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01321554>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1406470> ;
  nuclide:status "positive" ;
  nuclide:phase "3" ;
  nuclide:indications <https://nuclide.cc/indications/thyroid/> .